| A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects (NCT07670884) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-24 |
| Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B (NCT07606950) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-17 |
| A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus (NCT07599410) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-14 |
| A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants (NCT07681479) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis (NCT07660848) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis (NCT07709910) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants (NCT06506175) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting (NCT07709897) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity (NCT07690826) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity (NCT07559136) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-06-12 |
| A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease (NCT07551492) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-05-29 |
| Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (NCT07308392) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-02-25 |
| Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension (NCT07297797) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2026-01-14 |
| Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention (NCT07318103) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-12-31 |
| A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity (NCT07285902) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-12-25 |
| HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. (NCT07233070) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-10-31 |
| A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (NCT07185776) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-10-21 |
| Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects (NCT07150962) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-10-15 |
| A Single Ascending Dose of HRS-2162 in Healthy Subjects (NCT07195604) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-09-25 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy (NCT06994650) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-08-13 |
| A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia (NCT07100418) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-08-12 |
| A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity (NCT06974851) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-07-25 |
| Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin (NCT07060456) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-07-25 |
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection (NCT06934408) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-05-08 |
| Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects (NCT06855147) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-04-21 |
| Efficacy and Safety of HRS9531 Tablet in Obese Subjects (NCT06841445) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-04-07 |
| The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution (NCT06792955) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-02-11 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study. (NCT07117474) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-12-24 |
| Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects (NCT06723691) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-12-18 |
| A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects (NCT06732154) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-12-02 |
| the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone (NCT06650007) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-11-08 |
| A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes (NCT06649344) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-10-31 |
| HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents (NCT06554184) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-09-03 |
| A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome (NCT06595797) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-09-01 |
| A Study of HRS-9057 in Patients With Heart Failure and Volume Overload (NCT06506994) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-08-16 |
| A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects (NCT06541457) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-08-15 |
| Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial (NCT06447415) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-08-06 |
| A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea (NCT06565871) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-08-01 |
| A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults (NCT06475846) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-06-25 |
| A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects (NCT06435676) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-06-04 |
| To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese (NCT06396429) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-05-13 |
| HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction (NCT06391710) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-05-06 |
| A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis (NCT06194201) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-04-27 |
| A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects (NCT06246175) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-02-28 |
| Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects (NCT06054698) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-10-16 |
| A Trial of HRS-7450 in Chinese Healthy Volunteers (NCT06087094) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-10-01 |
| Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects (NCT05966272) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-08-12 |
| Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes (NCT05881837) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-06-13 |
| A Relative Bioavailability Study of HRS9531 in Healthy Subjects (NCT05893576) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-05-15 |
| Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B (NCT05808374) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-04-30 |
| A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition (NCT05788588) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2023-04-28 |
| A Study of Remimazolam Tosilate for Sedation in the ICU (NCT05152303) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2022-10-12 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus (NCT05516966) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2022-10-12 |
| Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors (NCT05509634) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2022-09-21 |
| Study of HR20013 for Injection in Patients With Malignant Solid Tumors (NCT05465681) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2022-08-30 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects (NCT05152277) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2021-12-06 |